Is PT-141 (Bremelanotide) Legal in Washington State?

HealthRX.com

No Washington-specific rule found for PT-141

Print or save as PDF

See the public record for Bremelanotide

  • Federal status / Prescription-only; FDA-approved as Vyleesi, June 21, 2019 [1][2]
  • Approved use / Premenopausal women with acquired, generalized HSDD [1]
  • Not indicated for / Men, postmenopausal women, or enhancing sexual performance [1]
  • Washington-specific rule / None found
  • FDA bulk-substance lists / Bremelanotide in no category [4][5]
  • Approved dose / 1.75 mg subcutaneous, at least 45 minutes before activity [1]
  • Contraindications / Uncontrolled hypertension or known cardiovascular disease [1]

What federal law says about bremelanotide

Vyleesi is the FDA-approved bremelanotide product. Its approval (NDA 210557) dates to June 21, 2019, and the application is now held by Cosette Pharmaceuticals, which took it over from AMAG [1][2]. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector and is prescription-only [1].

The approved use is narrow: premenopausal women with acquired, generalized HSDD, meaning low desire causing marked distress or interpersonal difficulty that is not due to a medical or psychiatric condition, relationship problems, or a medication or drug. The label says it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].

Washington State

We found no Washington-specific rule on bremelanotide. The established position is federal and applies nationwide: Vyleesi is an FDA-approved, prescription-only drug [1][2].

Questions worth asking

Choose the questions you want to keep

'PT-141' sold as a peptide is a different product

Compounded bremelanotide and PT-141 sold for research use are not Vyleesi and are not FDA-approved drugs. Compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before marketing [3][1].

Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks (page content dated April 22, 2026) [4], it is not in any category on FDA's bulk-substance lists [5], and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6].

Prescription PT-141 information is available at PT-141.

What the label says about using it

The labeled dose is 1.75 mg under the skin of the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The label says not to give more than one dose within 24 hours, that more than 8 doses per month is not recommended, and to stop after 8 weeks if symptoms have not improved [1].

Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease and is not recommended in patients at high risk for cardiovascular disease [1]. Each dose briefly raises blood pressure: the maximal increases in clinical studies were 6 mmHg systolic and 3 mmHg diastolic, while an ambulatory study of 127 premenopausal women dosed once daily for 8 days found mean daytime increases of 1.9 and 1.7 mmHg [1].

Athletes

Bremelanotide is not named on WADA's 2026 Prohibited List. Because bremelanotide is FDA-approved as Vyleesi, WADA's S0 class for substances with no approval from any governmental health authority does not apply by definition [1][7].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. What did the article find about Washington State rules on bremelanotide?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is PT-141 legal in Washington State?
We found no Washington-specific rule on bremelanotide. The federal position is that Vyleesi, the FDA-approved bremelanotide product, is prescription-only [1][2].
Is PT-141 FDA-approved?
Yes, as Vyleesi (NDA 210557), approved June 21, 2019, for premenopausal women with acquired, generalized HSDD. The label says it is not indicated for men, postmenopausal women, or to enhance sexual performance [1][2].
Is compounded or research-use PT-141 the same as Vyleesi?
No. Those products are not Vyleesi and are not FDA-approved drugs [3][1].
What is the approved dose?
The label says 1.75 mg under the skin of the abdomen or thigh at least 45 minutes before sexual activity, with no more than one dose in 24 hours. It says more than 8 doses a month is not recommended, and to stop after 8 weeks if symptoms have not improved [1].
Show all 7 referencesHide references
PT-141 legal Washington: evidence summary chart
Image: HealthRX.com. Full PT-141 legal Washington guide and sources at healthrx.com/peptide-legal-pt-141.